Vascular calcification (VC) is highly prevalent in aging, diabetes mellitus, and chronic kidney
disease (CKD). VC is a strong predictor of cardiovascular morbidity and mortality in the CKD …

Biochemical markers of bone turnover have been used for decades in the management of
bone diseases, to assess the prognosis of these conditions and to monitor treatments. The …

An elevated level of fibroblast growth factor-23 (FGF-23) is the earliest abnormality of
mineral metabolism in CKD. High FGF-23 levels promote left ventricular hypertrophy but not …

Results Patients were followed for 2.6 (interquartile range, 1.4–3.6) years. sKlotho tertiles
predicted neither atherosclerotic events/death (fully adjusted Cox regression analysis …

Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet
available therapies only modestly improve clinical outcomes. Observational studies report …

Coronary artery calcifications (CACs) are observed in most patients with CKD on dialysis
(CKD-5D). CACs frequently progress and are associated with increased risk for …

Biomarkers of Vascular Calcification and Mortality in Patien... : Clinical Journal of the
American Society of Nephrology Biomarkers of Vascular Calcification and Mortality in …

Abstract Purpose of Review Fibroblast growth factor 23 (FGF23) is a key phosphate-
regulating hormone that has been associated with adverse outcomes in patients with …

Fibroblast growth factor-23 is a bone-derived hormone that increases urinary phosphate
excretion and inhibits hydroxylation of 25-hydroxyvitamin D. Recent studies suggest that …

Arterial stiffness is an important risk factor for cardiovascular morbidity and mortality in
patients with end-stage renal disease (ESRD). Arterial stiffness aggravates cardiovascular …